|
Towia A. Libermann, PhD
co-Director,
99 Brookline Avenue
Boston, MA 02115
phone: 617-667-0760
fax: 617 -667-0891
email:tliberma@bidmc.harvard.edu
Research Abstract
The Libermann laboratory focuses on a group of novel Ets family transcription factors that they identified within the past several years. These Ets family members are expressed selectively in various types of epithelia, and their expression is deranged in several types of carcinoma. The laboratory uses gene knockout and over-expression approaches, combined with genomic and proteomic strategies, to elucidate the consequences of Ets protein dysregulation and the targets of these transcription factors, respectively. The laboratory also studies the mechanism of regulation of IL6 expression in prostate carcinogenesis and its potential role in directing androgen resistance and/or bone metastasis. The laboratory is furthermore applying various cutting edge technologies for proteomics, transcriptional profiling and genotyping in order to define and compare protein and gene profiles and genomic DNA in kidney, ovarian, prostate and breast cancer tissues, correlate protein and gene profiles and mutations with biological activities and disease, define disease mechanisms at a molecular level and predict clinical outcome and response to therapy. Further studies in the lab are focused on mechanisms of action of anti-cancer drugs on prostate, renal, ovarian and breast cancer cells using transcriptional profiling and genotyping approaches in order to identify putative novel points of entry for rational drug design, target validation, and identification of potential genes involved in adverse drug responses or drug resistance. Dr. Libermann is the Director of the DF/HCC Cancer Proteomics Core and of the BIDMC Genomics Center, which provide core assistance to medical center investigators in the use of various proteomics and expression technologies.
|
|
Manoj K. Bhasin, PhD
co-Director,
99 Brookline Avenue
Boston, MA 02115
phone: 617-667-0009
fax: 617 -667-0891
email:mbhasin@bidmc.harvard.edu
Research Abstract
The Bhasin laboratory focuses on development of novel methods for analysis of genome level data and integrative systems biology oriented analysis of multidimensional disease related data. Dr. Bhasin is an experienced Bioinformatician with a strong track record in computational vaccine design, functional genomics, proteomics and systems biology with over 50 scientific Publications and several tools and algorithms for data analysis. Dr. Bhasin has strong interests in development of computational methods for systems level integrative analysis of multidimensional genome level data (e.g. mRNA, miRNA, methylation profiling and proteomics) and identifying novel diagnostics, progression and therapeutic biomarkers for renal and pancreatic cancers. In collaboration with leading investigators at Harvard, Dr. Bhasin has worked on a variety of approaches to identify gene(s)/protein(s) /microRNA(s) that are currently being evaluated as biomarkers and/or targets for therapeutic interventions. He is applying and developing systematic analysis strategies for high-throughput transcriptional profiling, epigenomics, genotyping, proteomics, and metabolomics data to improve molecular understanding of diseases and to identify novel diagnostics, prognostic and therapeutics biomarkers. Please see Google Scholars for list of publications.
|
